Stocks · News reference

HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $7 Price Target

Aug 26, 2026, 11:28 AMBenzinga Newsdesk

HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $7 price target.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARSep 4, 2026, 9:25 PMSEC EDGAR
8-K filing — PDS Biotechnology Corp (PDSB)
Filed: 2026-09-04 AccNo: 0001140361-26-035809 Size: 199 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits
PDSB
BenzingaAug 25, 2026, 8:11 PMBenzinga Newsdesk
PDS Biotechnology Intends To Cut Workforce By 36%; Removes Stephan Toutain As COO, Effective Aug. 21
SEC.
PDSB
BenzingaAug 19, 2026, 9:00 PMBenzinga Newsdesk
PDS Biotechnology Says Lars Boesgaard To Resign As CFO, Principal Financial Officer & Principal Accounting Officer Effective Sept 12; Frank Bedu-Addo Appointed As Interim Principal Financial Officer
On August 13, 2026, Lars Boesgaard submitted his resignation, effective as of September 12, 2026, as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corporation
PDSB